Pandora, Gap Post R...
Health Care: Drugs
DepoMed Inc. (DEPO: NASDAQ)
$5.79 0.08 | 1.40%
05/23/13 - 04:00 PM ET
Company Balance Sheet
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Assets | ||||
|---|---|---|---|---|
| Cash and Equivalents | 29.08M | 24.04M | 22.53M | 26.82M |
| Receivables | 13.69M | 12.56M | 6.35M | 4.93M |
| Inventories | 9.59M | 5.40M | 1.57M | 2.56M |
| Other Current Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Current Assets | 95.27M | 109.49M | 79.60M | 78.43M |
| Property, Plant & Equipment, Gross | 16.31M | 9.42M | 8.83M | 8.97M |
| Accumulated Depreciation & Depletion | 8.08M | 8.35M | 8.13M | 8.03M |
| Property, Plant & Equipment, Net | 8.24M | 1.07M | 698.00K | 942.00K |
| Intangibles | 25.08M | 0.00 | 0.00 | 0.00 |
| Other Non-Current Assets | 13.07M | 53.81M | 6.73M | 12.21M |
| Total Non-Current Assets | 46.39M | 54.88M | 7.43M | 13.16M |
| Liabilities & Shareholder Equity | ||||
| Total Assets | 141.65M | 164.37M | 87.03M | 91.58M |
| Accounts Payable | 2.36M | 2.42M | 18.47M | 4.07M |
| Short Term Debt | 0.00 | 0.00 | 2.17M | 3.75M |
| Other Current Liabilities | 830.00K | 64.00K | 635.00K | 414.00K |
| Total Current Liabilities | 36.68M | 39.84M | 32.98M | 32.20M |
| Long Term Debt | 0.00 | 0.00 | 0.00 | 2.17M |
| Deferred Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Liabilities | 21.04M | 18.61M | 30.94M | 41.48M |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Non-Current Liabilities | 21.04M | 18.61M | 30.94M | 43.65M |
| Total Liabilities | 57.72M | 58.45M | 63.92M | 75.86M |
| Preferred Stock Equity | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Stock Equity | 83.94M | 105.92M | 23.11M | 15.73M |
| Common Par | 0.00 | 0.00 | 0.00 | 0.00 |
| Additional Paid In Capital | 211.27M | 203.51M | 191.34M | 187.90M |
| Cumulative Translation Adjustment | 0.00 | 0.00 | 0.00 | 0.00 |
| Retained Earnings | -127.36M | -97.58M | -168.31M | -172.20M |
| Treasury Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Equity Adjustments | 31.00K | -13.00K | 69.00K | 33.00K |
| Total Capitalization | 83.94M | 105.92M | 23.11M | 17.90M |
| Total Equity | 83.94M | 105.92M | 23.11M | 15.73M |
| Total Liabilities & Stock Equity | 141.65M | 164.37M | 87.03M | 91.58M |
| Total Common Shares Outstanding | 56.38M | 55.51M | 52.96M | 52.20M |
| Preferred Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Treasury Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic Weighted Shares Outstanding | 55.89M | 54.56M | 52.53M | 51.52M |
| Diluted Weighted Shares Outstanding | 55.89M | 56.09M | 53.46M | 51.52M |
| Number of Employees | 267 | 110 | 69 | 73 |
| Number of Part-Time Employees | 0 | 0 | 0 | 0 |
Portfolios with DEPO
- Portfolio NameUser Type
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
- ContributorEarnings Short Squeeze Play...
- Usertracking
- UserAccelerant
- UserRASHID 1
- UserPortfolio 02
- UserJan Jan Portfolio 1
- Contributor10 Surging Stocks Most at R...
Latest DEPO Headlines from TheStreet
- Short Interest In DepoMed Moves 11% Lower 04.25.13 | 04:04 pm
- Top 10 Trending On StockTwits At The Close (March 4) 03.04.13 | 06:03 pm
- Depomed FDA Panel Live Blog 03.04.13 | 07:03 am
- Biotech Stock Mailbag: Ziopharm, Oncolytics, Sarepta 03.01.13 | 06:03 am
- The Next Big Thing In Biotech: DepoMed
02.28.13 | 09:02 am - Depomed Inc. Stock Upgraded (DEPO) 02.22.13 | 04:02 am
- 5 Stocks Under $10 Triggering Breakouts 02.21.13 | 12:02 pm
- Depomed Bear Case: FDA Panel Will Ding Serada 02.04.13 | 08:02 am
- Stocks Under $5: Stealth Healthcare Play 12.19.12 | 11:12 am
- 2013 FDA Drug Approval Decision Calendar 12.19.12 | 09:12 am
Press Releases for DEPO
- Depomed To Present At Roth Capital Partners 25th Annual Growth Stock Conference - PR Newswire 03.13.13 | 04:03 pm
- Depomed Provides Update On SEFELSAâ¿¢ FDA Advisory Committee - PR Newswire 03.04.13 | 01:03 pm
- Trading Of Depomed Common Stock Halted - PR Newswire 03.04.13 | 07:03 am
- Depomed To Present At Cowen And Company Health Care Conference - PR Newswire 02.26.13 | 04:02 pm
- Depomed To Report Fourth Quarter Fiscal Year 2012 Financial Results On Wednesday, February 20, 2013 - PR Newswire 02.13.13 | 04:02 pm
- Depomed Announces Appointment Of Vicente J. Anido, Jr., Ph.D. To Board Of Directors, And Retirement Of Directors Julian N. Stern And Craig R. Smith, M.D. - PR Newswire 02.11.13 | 08:02 am
- EmergingGrowth.com Special Report On RVPlus, Inc., Oil And Gas, And Patents Infringement In Pharmaceuticals - PR Newswire 12.28.12 | 08:12 am
- Depomed Announces Dismissal Of Suit Against Two Gralise ANDA Filers Following Withdrawal Of ANDA And Patent Challenge - PR Newswire 12.26.12 | 04:12 pm
- Depomed To Present At Oppenheimer 2012 Healthcare Conference - PR Newswire 12.03.12 | 04:12 pm
- Depomed To Present At Piper Jaffray 2012 Healthcare Conference - PR Newswire 11.19.12 | 04:11 pm
Partner Headlines for DEPO
- FDA Panel Kills Sefelsa, Creates Buying Opportunity In Depomed Stock - Seeking Alpha 03.05.13 | 09:03 am
- Roth Capital's Henry Sees Upcoming FDA Panel For Depomed's Sefelsa As A Coin Flip - Seeking Alpha 03.01.13 | 05:03 pm
- Serada Approval Presents Big Upside To Depomed - Seeking Alpha 01.30.13 | 09:01 am
- 5 Pharmaceutical Companies With Insider Buying During August 14-16 - Seeking Alpha 08.19.12 | 05:08 am
- Sell-Offs PROMPT Buying Opportunity for VF Corp. and 3 More Hot Analyst Alerts - Wall St. Cheat Sheet 06.21.12 | 03:06 am
- New Constructs' Most Attractive Stocks for June - Benzinga 06.04.12 | 09:06 am
- The Zacks Analyst Blog Highlights: Watson Pharmaceuticals, Shire, Depomed, Comcast and Microsoft - Press Releases - Zacks 05.18.12 | 09:05 am
- Company News for February 7, 2012 - Corporate Summary - Zacks 02.07.12 | 10:02 am
- 7 Healthcare Stocks Undervalued By Earnings Growth And Cash Flows - Seeking Alpha 02.03.12 | 07:02 pm
- Depomed Announces FDA Approval of Merck's JANUMET XR That Accesses Depomed Patents Licensed to Merck - Benzinga 02.03.12 | 04:02 pm
